Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Nibrozetone by EpicentRx for Oral Mucositis: Likelihood of Approval
Nibrozetone is under clinical development by EpicentRx and currently in Phase II for Oral Mucositis. According to GlobalData, Phase II...
Nibrozetone by EpicentRx for Small-Cell Lung Cancer: Likelihood of Approval
Nibrozetone is under clinical development by EpicentRx and currently in Phase III for Small-Cell Lung Cancer. According to GlobalData, Phase...
AdAPT-001 by EpicentRx for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
AdAPT-001 is under clinical development by EpicentRx and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
AdAPT-001 by EpicentRx for Leiomyosarcoma: Likelihood of Approval
AdAPT-001 is under clinical development by EpicentRx and currently in Phase II for Leiomyosarcoma. According to GlobalData, Phase II drugs...
AdAPT-001 by EpicentRx for Chordoma: Likelihood of Approval
AdAPT-001 is under clinical development by EpicentRx and currently in Phase II for Chordoma. According to GlobalData, Phase II drugs...
AdAPT-001 by EpicentRx for Chondrosarcoma: Likelihood of Approval
AdAPT-001 is under clinical development by EpicentRx and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II drugs...